| 18th IBD Intensive Advanced Course |
||
| 08:00-08:15 | Arrival and distribution of voting pads | |
| 08:15–08:30 | 1: Welcome & Introduction from the course director |
|
| 08:30–10:30 | Session 1: Introduction and case-based management on conventional IBD Therapies |
|
| 08:30-09:00 | 2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics | |
| 09:00-09:20 | 3: 5-ASA compounds | |
| 09:20-09:40 |
4: Thiopurines | |
| 09:40-10:00 |
5: Methotrexate | |
| 10:00-10:20 | 6: Steroids | |
| 10:20-10:30 | Discussion | |
| 10:30-10:50 | Coffee break | |
| 10:50-12:30 | Session 2: Case-based management of conventional IBD therapies |
|
| 10:50-11:10 | 7: Anti-TNF agents | |
| 11:10-11:30 | 8: Anti-integrins | |
| 11:30-11:50 | 9: Ustekinumab | |
| 11:50-12:10 | 10: Tofacitinib | |
| 12:10-12:30 | 11: Small molecules and biologics in the pipeline | |
| 12:30–14:00 | Lunch break | |
| 14:00-15:30 | Session 3: Round tables - 7 Themes/clinical cases discussion |
|
| 14:00-15:30 | 12a: Pregnancy 12b: Extraintestinal manifestations 12c: When and how to stop biologics? 12d: Complications associated with anti-TNF therapy 12e: Therapeutic Drug Monitoring 12f: Exit strategy 12g: Therapeutic Endoscopy in IBD |
|
| 15:30-15:50 | Coffee break | |
| 15:50-17:00 | Session 3: Round tables - 7 Themes/clinical cases discussion |
|
| 15:50-17:00 | 12a: Pregnancy 12b: Extraintestinal manifestations 12c: When and how to stop biologics? 12d: Complications associated with anti-TNF therapy 12e: Therapeutic Drug Monitoring 12f: Exit strategy 12g: Therapeutic Endoscopy in IBD |
|
18th IBD Intensive Advanced Course
| Date | February 12-13, 2020 | |
| Time | February 12 from 08:00 to 17:00 February 13 from 07:30 to 12:00 |
|
| Responsible Committee | EduCom | |
| Target audience | Junior gastroenterologists | |
| ECCO Membership 2020 required | Regular/Y-ECCO Membership | |
| Registration details |  Call for participants: 18th IBD Intensive Advanced Course at ECCO'20Registration fee and further details coming soon |